More mRNA Vaccines From Massachusetts
Massachusetts based Moderna, Inc. announced that it is expanding its mRNA vaccines with three new development programs. This announcement reflects the Company’s commitment to accelerating its infectious disease portfolio based on Moderna’s experience with its COVID-19 vaccine.
These mRNA vaccine candidates are against seasonal influenza, HIV, and the Nipah virus.
Stéphane Bancel, Moderna’s CEO, stated in a press release issued on January 11, 2021, “Even as we have shown that our mRNA-based vaccine can prevent COVID-19, this has encouraged us to pursue more-ambitious development programs within our prophylactic vaccines modality. Beyond vaccines, we are extending our mRNA development work to a total of 24 programs across five therapeutic areas.”
Moderna also announced an expansion of its respiratory syncytial virus vaccine program into older adults.